Investor Relations
Corporate Profile
Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Doylestown, Pennsylvania, focused on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. The Company’s lead program is ATRN-119, a Phase 1-ready small molecule ATR inhibitor being developed for solid tumor indications.
btn News
btn Events
NASDAQ: APRE
Data Provided by Refinitiv. Minimum 15 minutes delayed.